Biovica International Beheer

Beheer criteriumcontroles 1/4

De CEO Biovica International is Anders Rylander, benoemd in Jan2011, heeft een ambtstermijn van 13.83 jaar. bezit rechtstreeks 10.6% van de aandelen van het bedrijf, ter waarde SEK 17.24M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 8.8 jaar.

Belangrijke informatie

Anders Rylander

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	13.8yrs
Eigendom CEO	10.6%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	8.8yrs

Recente managementupdates

Recent updates

Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?

Jul 18

Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation

Dec 02

Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation

Aug 02

Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation

Feb 17

A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)

Jan 19

Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth

Nov 11

We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth

Aug 06

We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn

Mar 20

Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?

Feb 22

What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?

Jan 26

The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders

Dec 31

Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation

Dec 05

CEO

Anders Rylander (54 yo)

13.8yrs

Tenure

Mr. Anders Rylander serves as Chief Executive Officer of Biovica International AB (publ) since 2010 and serves as its President. Mr. Rylander is the Founder of Arinvest and Co-Founder of Axholmen. He has b...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Anders Rylander	President	13.8yrs	geen gegevens	10.6% SEK 17.2m
Anders Moren	Chief Financial Officer	1.8yrs	geen gegevens	0.081% SEK 132.2k
Hanna Ritzén	Chief Operating Officer	1.8yrs	geen gegevens	0.017% SEK 28.3k
Helle Fisker	Vice President of Commercial & Marketing	no data	geen gegevens	0.065% SEK 105.8k
Henrik Winther	Senior Vice President of Business Development	4.8yrs	geen gegevens	0.028% SEK 45.3k
Hector Tamburini	Head of US Laboratory Operations	1.8yrs	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BIOVIC B wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anders Rylander	President	14.8yrs	geen gegevens	10.6% SEK 17.2m
Lars Holmqvist	Independent Chairman of the Board	5.7yrs	SEK 481.00k	1.16% SEK 1.9m
Annika Berg	Independent Director	3.8yrs	SEK 200.00k	0.050% SEK 80.6k
Maria Holmlund	Independent Director	8.8yrs	SEK 263.00k	0.069% SEK 112.1k
Jarl Jungnelius	Independent Director	10.8yrs	SEK 219.00k	geen gegevens
Jesper Soderqvist	Independent Director	11.8yrs	SEK 250.00k	0.23% SEK 380.0k
Marie-Louise Fjallskog	Independent Director	4.8yrs	SEK 100.00k	geen gegevens

8.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIOVIC B wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).

Biovica International Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

President recently bought kr219k worth of stock

Insider recently sold kr55k worth of stock

Independent Chairman of the Board recently bought kr238k worth of stock

Independent Chairman of the Board recently bought kr284k worth of stock

Biovica International AB (publ), Annual General Meeting, Sep 17, 2024

Insufficient new directors

Recent updates

Biovica International AB (publ) to Report Q4, 2026 Results on Jun 17, 2026

Consensus revenue estimates fall by 26%

President recently bought kr219k worth of stock

New major risk - Financial position

First quarter 2025 earnings released: kr0.27 loss per share (vs kr0.70 loss in 1Q 2024)

Insider recently sold kr55k worth of stock

Independent Chairman of the Board recently bought kr238k worth of stock

Independent Chairman of the Board recently bought kr284k worth of stock

Consensus revenue estimates decrease by 64%, EPS upgraded

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biovica International AB (publ) Announces Divitum® Tka Results to Be Presented At Asco the Cancer Conference

Consensus EPS estimates upgraded to kr7.42 loss

New minor risk - Profitability

Forecast breakeven date pushed back to 2027

Biovica International AB (Publ) Announces Divitum® Tka in Observational Trial

New minor risk - Share price stability

Biovica International AB (publ) to Report Q4, 2025 Results on Jun 19, 2025

Biovica International AB (publ), Annual General Meeting, Sep 17, 2024

Price target decreased by 21% to kr15.00

Biovica Announces Interventional DiviTum TKa Trial Launches at Washington University

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biovica International AB (publ) has completed a Composite Units Offering in the amount of SEK 119.385023 million.

Forecast to breakeven in 2026

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare

New major risk - Market cap size

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial

Biovica International Achieves PLA code for Medicare

New minor risk - Share price stability

Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?

Full year 2023 earnings: EPS and revenues miss analyst expectations

Biovica International AB (publ) Announces A Poster with DivTum® TKa Results from the SWOG Study S0226

Third quarter 2023 earnings released

Biovica International Receives Clia Certification

Insufficient new directors

Biovica International Announces DiviTum(R) TKa Clinical Validation Data Published in Biomarkers

Chief Financial Officer recently bought kr148k worth of stock

Insider recently bought kr149k worth of stock

Second quarter 2023 earnings released

Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation

Biovica International AB (publ) Appoints Anders Morén as CFO

Biovica Submits CLIA Lab Application for DiviTum(R)TKa Launch

First quarter 2023 earnings released

Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation

Biovica International AB (publ) Receives FDA Approval for DiviTum®TKa

Biovica International AB (Publ) Announces Resignation of Cecilia Driving as deputy CEO, Effective December 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biovica International Announces DiviTumTKa Predicts Clinical Outcome of Patients in BioitaLEE Study

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biovica International AB Announces Nomination Committee Appointments

Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation

Biovica Announces Positive DiviTum®TKa Results from the European Multicenter Study PYTHIA Have Been Published in the Highly Ranked Peer-Reviewed Scientific Journal European Journal of Cancer

Now 23% undervalued after recent price drop

CEO & Director recently bought kr165k worth of stock

Now 21% undervalued after recent price drop

Independent Chairman of the Board recently bought kr315k worth of stock

A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biovica announces the start of the TK IMPACT trial at Washington University of St Louis

Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth

We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth

Independent Chairman of the Board recently bought kr622k worth of stock

Forecast to breakeven in 2024

Full year 2021 earnings released: kr1.39 loss per share (vs kr1.29 loss in FY 2020)

Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma

We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn

Consensus forecasts updated

Biovica International AB (publ), Annual General Meeting, Aug 31, 2021